Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Reindl-Schwaighofer, 2021

Janssen AD26 vaccine (JNJ-78436735) (n=100) vs. Comirnaty (tozinameran - Pfizer/BIONTECH) (n=101)

randomized controlled trial   risk of bias NA

Studied treatment

Ad26COVS1 vaccine

Control treatment

homologous (mRNA) vaccine

mRNA (BNT162b2 or mRNA-1273) or vector (Ad26COVS1) as a third dose of a SARS-CoV-2 vaccine after 2 doses of an mRNA vaccine

Patients

COVID-19 prophylaxis (excluding children)

Method

single-blinded

1 center, Austria

Remark

Sadoff, 2021 NCT04436276

Janssen AD26 vaccine (JNJ-78436735) (n=-9) vs. placebo (n=-9)

randomized controlled trial   risk of bias NA

Studied treatment

Control treatment

placebo

five arms: low dose followed by low dose, low dose followed by placebo, high dose followed by high dose, high dose followed by placebo, and placebo followed by placebo cohorts 1 and 3 were grouped together regardless of the dose received

Patients

COVID-19 prophylaxis (excluding children)

Method

double-blind

12 centers in Belgium and the United States

Remark

ENSEMBLE (COV3001), 0 NCT04505722

Janssen AD26 vaccine (JNJ-78436735) (n=21895) vs. placebo (n=21888)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Janssen Ad26.COV2.S vaccine single dose (5x1010 vp) intramuscular

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

double blind

Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States

Remark